Other

Snu Rdb Foundation

Young Hee Kim

Young Bok Han

Seoul Pharm. Co., Ltd.

Tae Rim Pharm. Co., Ltd.

Apharma

Sang Geon Kim

Eun Kyung Hong

Sung Hwan Ki

Bo Im Yoo

Kyung Yung Lee

Tae Hyun Kim

Ho-Young Reho Lee

Jeong Hun Kim

Mi Kyung Kim

Jong Bae Kim

Jong Wook Lee

Won Keun Kim

Young-Ger Suh

Kyu-Won Kim

Seungbeom Lee

Nak Doo Kim

Yeonseok Chung

Young Shin Chung

Hong Ki Kyung

Hae Kyung Kwon

Soon Kyoung Kwon

Hee Sook Choi

Yung Bok Han

Chun Won Kim

E Tay Ahn

Hyo Suk Lee

Hea Soon Shin

Sung Hee Choi

Hongchan An

Young Nam Park

Young Ro Choi

Seong Hwan Hwang

Jae Hoon Choi

Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.

Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance

A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1&#x3b1;, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient

Provided is a pharmaceutical composition that contains a 1,2-dithiolthionederivative, and is effective to prevent and treat a disease caused by overactivity of a liver X receptor&#x3b1; (LXR&#x3b1;) or a sterol response element binding protein (SREBP-1). Specifically, the pharmaceutical composition includes 1,2-dithiolthione derivatives such as 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione, 3-methyl-1,2-dithiol-3-thione, or 5-(6-methoxypyrazinyl)-4-methyl-1,2-dithiol-3-thione. The pharmaceutical composition is effective for preventing and treating hypertension caused by renin, aldosteronism, adrenoleukodystrophy, glomerulosclerosis, proteinuria, nephropathy, liver steatosis, hypertriglyceridemia or hyperreninemia.

Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-&#x3b1;

Provided is a pharmaceutical or food or drink composition for preventing or treating alcohol-induced fatty liver or steatohepatitis comprising metadoxine (pyridoxol 1-2-pyrrolidone-5-carboxylate) and garlic oil as active ingredients. The concurrent administration of metadoxine and garlic oil according to the present invention exhibits outstandingly superior effects of inhibiting the accumulation of triglyceride and increase of blood AST (aspartate aminotransferase) level in liver el tissue, inhibiting the expression of FAS (fatty acid synthase), CYP2E1 and iNOS (inducible nitric oxide synthase) and inhibiting the deactivation of AMPK (AMP-activated protein kinase), as compared to the administration of metadoxine or garlic oil only.

Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis

Pharmaceutical composition containing a mixed extract of Phellodendron

The, present invention relates to a novel allylthiopyridazine derivative represented by formula (I) which exhibits a superior effect for prevention and treatment or hepatic diseases induced by toxic substances and for protection of human tissues from radiation: ##STR1## or a pharmaceutically acceptable salt thereof, in which R.sub.1 represents halogen atom, lower alkoxy, dialkylaminoalkoxy, hydroxyalkoxy, phenoxy substituted or unsubstituted with lower alkyl, benzyloxy, or phenyl, and

Allylthiopyridazine derivatives and process for preparing the same

The present invention relates to an anti-cancer composition containing acridine derivatives and guanosine compounds. In the composition of the present invention, the acridine derivative and the guanosine compound are present in the weight ratio of 1:0.1-5.0, preferably 1:0.3-3.0 and more preferably 1:0.5-1.5. In the composition of the present invention, most preferably the acridine derivative is acriflavine neutral and the guanosine compound is guanosine hydrate. Although acridine derivatives and guanosine compounds used as an active ingredient in the present composition have substantially no anti-cancer effect when they are used individually, the combination of acriflavine neutral and guanosine hydrate which potentiates the effect of acriflavine neutral, i.e. the composition(AG60) according to the present invention, exhibits reduced toxicity and increased anti-cancer effect in comparison to the use of acriflavine neutral or guanosine hydrate alone.

Anti-cancer compositions

Chemopreventive compounds and a preparation method and use thereof

Growing community of inventors

Seoul, South Korea

Sang Geon Kim